Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542451 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT00542451 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 406 participants.
The verdict
NCT00542451, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effect the postoperative combination of therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node positive and high risk node negative disease. This tests utilizes a well tolerated regimen of weekly paclitaxel and trastuzumab in women with T1, node negative tumors that are HER2 positive. We would like to determine how effective this drug combination is when used in women with early stage breast cancer, as well as to better define the side effects of this treatment.
Interventions
- DRUG Trastuzumab
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2007-10 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542451
The ClinicalTrials.gov registry entry for NCT00542451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00542451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00542451 about?
NCT00542451 is a clinical study titled "Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer". The purpose of this study is to find out what effect the postoperative combination of therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node positive and high risk node negative d...
What is the current status of trial NCT00542451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2007-10. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT00542451?
The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00542451?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.